<?xml version="1.0" encoding="us-ascii"?><InstanceReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><Version>2.4.0.8</Version><ReportLongName>107 - Disclosure - Summary of Significant Accounting Policies</ReportLongName><DisplayLabelColumn>true</DisplayLabelColumn><ShowElementNames>false</ShowElementNames><RoundingOption /><HasEmbeddedReports>false</HasEmbeddedReports><Columns><Column FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><CurrencyCode /><FootnoteIndexer /><hasSegments>false</hasSegments><hasScenarios>false</hasScenarios><MCU><KeyName /><CurrencySymbol /><contextRef><ContextID>P01_01_2013To06_30_2013</ContextID><EntitySchema>http://www.sec.gov/CIK</EntitySchema><EntityValue>0001124608</EntityValue><PeriodDisplayName /><PeriodType>duration</PeriodType><PeriodStartDate>2013-01-01T00:00:00</PeriodStartDate><PeriodEndDate>2013-06-30T00:00:00</PeriodEndDate><Segments /><Scenarios /></contextRef><UPS /><CurrencyCode /><OriginalCurrencyCode /></MCU><CurrencySymbol /><Labels><Label Key="CalendarSupplement" Id="0" Label="6 Months Ended" /><Label Key="Calendar" Id="1" Label="Jun. 30, 2013" /></Labels></Column></Columns><Rows><Row FlagID="0"><Id>1</Id><IsAbstractGroupTitle>true</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>1</Level><ElementName>us-gaap_AccountingPoliciesAbstract</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText /><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>xbrli:stringItemType</ElementDataType><SimpleDataType>string</SimpleDataType><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Accounting Policies [Abstract]</Label></Row><Row FlagID="0"><Id>2</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>2</Level><ElementName>us-gaap_SignificantAccountingPoliciesTextBlock</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><PreferredLabelRole>verboseLabel</PreferredLabelRole><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="P01_01_2013To06_30_2013" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText>              &lt;table border="0" style="clear:both;width:100%; table-layout:fixed;"&gt;  &lt;tr&gt;  &lt;td&gt;&lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;2. Summary of Significant Accounting  Policies&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Basis of Consolidation&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The consolidated financial statements include the accounts of the  Company and its wholly owned subsidiary, Response Genetics, Ltd., a  Scottish corporation (the &amp;#8220;Subsidiary&amp;#8221;), which was  incorporated in November 2006. The Subsidiary had no employees or  active operations in 2012 or to date in 2013. All significant  intercompany transactions and balances have been eliminated in  consolidation.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Reclassification&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Certain reclassifications have been made to prior period amounts to  conform to current period presentation. These reclassifications did  not have an impact on the Company&amp;#8217;s financial condition as of  December 31, 2012 or at June 30, 2013.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Cash and Cash Equivalents&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company considers all highly liquid investments with a maturity  date of three months or less from the date of purchase to be cash  equivalents. The carrying value of cash equivalents approximates  fair value due to the short-term nature and liquidity of these  instruments. The Company&amp;#8217;s cash equivalents are comprised of  cash on hand, deposits in banks and money market investments.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;font style="TEXT-INDENT: 0in; MARGIN: 0in" size="2"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 9pt"&gt;  &lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;font style="TEXT-INDENT: 0in; MARGIN: 0in" size="2"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 9pt"&gt;&lt;em&gt;  Accounts Receivable&lt;/em&gt;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;u&gt;Pharmaceutical Accounts Receivable&lt;/u&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company invoices its clients as specimens are processed and any  other contractual obligations are met. The Company&amp;#8217;s  contracts with clients typically require payment within &lt;font  style=" FONT-SIZE: 10pt"&gt;45&lt;/font&gt; days of the date of invoice. The  Company maintains allowances for doubtful accounts for estimated  losses resulting from the inability of its clients to make required  payments. The Company specifically analyzes accounts receivable and  historical bad debts, client credit, current economic trends and  changes in client payment trends when evaluating the adequacy of  the allowance for doubtful accounts. Account balances are charged  against the allowance when it is probable the receivable will not  be recovered. To date, the Company&amp;#8217;s pharmaceutical customers  have primarily been large pharmaceutical companies. As a result,  bad debts from pharmaceutical accounts receivable to date have been  minimal. Pharmaceutical company accounts receivable as of December  31, 2012 and June 30, 2013 were $&lt;font style=" FONT-SIZE: 10pt"&gt;2,549,665&lt;/font&gt; and $&lt;font style=" FONT-SIZE: 10pt"&gt;2,360,808&lt;/font&gt;, respectively. There were no  allowances for doubtful accounts recorded against these  pharmaceutical accounts receivable at December 31, 2012 and June  30, 2013.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;u&gt;ResponseDX&lt;/u&gt;&lt;sup&gt;&amp;#174;&lt;/sup&gt; &lt;u&gt;Accounts Receivable&lt;/u&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  ResponseDX&lt;sup&gt;&amp;#174;&lt;/sup&gt; accounts receivable are recorded from  two primary payors: (1) Medicare and (2) third party payors such as  commercial insurance and private payors or self-paying  payors&amp;#160;(&amp;#8220;Private Payors&amp;#8221;).  ResponseDX&lt;sup&gt;&amp;#174;&lt;/sup&gt; accounts receivable are recorded at  established billing rates less an estimated billing adjustment,  based on reporting models utilizing historical cash collection  percentages and updated for current effective reimbursement  factors. Management performs ongoing valuations of accounts  receivable balances based on management&amp;#8217;s evaluation of  historical collection experience and industry trends. Based on the  historical experience for our Medicare and Private Payor accounts,  management has determined, based on a detailed analysis, that  accounts receivable associated with certain billings are unlikely  to be collected. Therefore, the Company has recorded an allowance  for doubtful accounts of $&lt;font style=" FONT-SIZE: 10pt"&gt;991,990&lt;/font&gt; and $&lt;font style=" FONT-SIZE: 10pt"&gt;903,961&lt;/font&gt; as of December 31, 2012 and June  30, 2013, respectively. The Company&amp;#8217;s bad debt expense for  the three months ended June 30, 2012 and 2013 was $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;51,340&lt;/font&gt;&lt;/font&gt;  and $&lt;font style=" FONT-SIZE: 10pt"&gt;349,984&lt;/font&gt;, respectively,  and for the six months ended June 30, 2012 and 2013 was $&lt;font  style=" FONT-SIZE: 10pt"&gt;307,265&lt;/font&gt; and $&lt;font style=" FONT-SIZE: 10pt"&gt;818,451&lt;/font&gt;, respectively.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  ResponseDX&lt;sup&gt;&amp;#174;&lt;/sup&gt; accounts receivable as of December 31,  2012 and June 30, 2013, consisted of the following:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt" align="center"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 92%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="68%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;December&amp;#160;31,&lt;br/&gt;   2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;June&amp;#160;30,&lt;br/&gt;   2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="68%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="11%" colspan="2"&gt;  &lt;div&gt;(Unaudited)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="68%"&gt;  &lt;div&gt;Net Medicare receivable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;890,936&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,930,801&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="68%"&gt;  &lt;div&gt;Net Private Payor receivable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,924,412&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,062,043&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="68%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,815,348&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;4,992,844&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="68%"&gt;  &lt;div&gt;Allowance for doubtful accounts&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(991,990)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(903,961)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="68%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,823,358&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;4,088,883&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Property and Equipment&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Property and equipment are carried at cost less accumulated  depreciation and amortization. Depreciation and amortization are  calculated using the double declining balance and straight-line  methods over the estimated useful lives of the assets. The Company  has determined the estimated useful lives of its property and  equipment, as follows:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0in; MARGIN: 0in; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt;    &lt;table style="clear:both;WIDTH: 100%; BORDER-COLLAPSE: collapse"  border="0" cellspacing="0" cellpadding="0" width="100%"&gt;  &lt;tr&gt;  &lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #ece9d8 0px; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 38%; PADDING-RIGHT: 0in; VERTICAL-ALIGN: top; BORDER-TOP: #ece9d8 0px; BORDER-RIGHT: #ece9d8 0px; PADDING-TOP: 0in"   width="50%"&gt;  &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 50%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"   valign="top" width="50%"&gt;  &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;5 to 7 years&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr&gt;  &lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #ece9d8 0px; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 38%; PADDING-RIGHT: 0in; VERTICAL-ALIGN: top; BORDER-TOP: #ece9d8 0px; BORDER-RIGHT: #ece9d8 0px; PADDING-TOP: 0in"   width="50%"&gt;  &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Furniture and Equipment&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 50%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"   valign="top" width="50%"&gt;  &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;3 to 7 years&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr&gt;  &lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: #ece9d8 0px; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 38%; PADDING-RIGHT: 0in; VERTICAL-ALIGN: top; BORDER-TOP: #ece9d8 0px; BORDER-RIGHT: #ece9d8 0px; PADDING-TOP: 0in"   width="50%"&gt;  &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #ece9d8; BORDER-LEFT: #ece9d8; PADDING-BOTTOM: 0in; BACKGROUND-COLOR: transparent; PADDING-LEFT: 0in; WIDTH: 50%; PADDING-RIGHT: 0in; BORDER-TOP: #ece9d8; BORDER-RIGHT: #ece9d8; PADDING-TOP: 0in"   valign="top" width="50%"&gt;  &lt;div style="clear:both;MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Shorter of the useful life (5 to 7 years) or the  lease term&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Maintenance and repairs are charged to expense as incurred. The  cost and accumulated depreciation of assets sold or otherwise  disposed of are removed from the related accounts and the resulting  gain or loss is reflected in the statements of operations. The  Company has capitalized costs related to the development of  database software (see Note 3). The portion of this database placed  into service is amortized in accordance with ASC 350-40, &lt;em&gt;  Internal-Use Software&lt;/em&gt;. The amortization period is five years  using the straight-line method.&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Revenue Recognition&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Pharmaceutical Revenue&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Revenues that are derived from testing services provided to  pharmaceutical companies are recognized on a contract specific  basis pursuant to the terms of the related agreements. Revenue is  recognized in accordance with ASC 605, &lt;em&gt;Revenue  Recognition,&lt;/em&gt; which requires that four basic criteria must be  met before revenue can be recognized: (1) persuasive evidence that  an arrangement exists; (2) delivery has occurred and title and the  risks and rewards of ownership have been transferred to the client  or services have been rendered; (3) the price is fixed or  determinable; and (4) collectability is reasonably assured.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Revenues are recorded on an accrual basis as the contractual  obligations are completed and as a set of assays is processed  through the Company&amp;#8217;s laboratory under a specified  contractual protocol and are recorded on the date the tests are  completed. Certain contracts have minimum assay requirements that,  if not met, result in payments that are due upon the completion of  the designated period. In these cases, revenues are recognized when  the end of the specified contract period is reached.&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="times new roman,times,serif"&gt;In March 2012, the  Company entered into a non-exclusive license agreement with  GlaxoSmithKline, LLC, which calls for payments to be made to the  Company when certain events specified in the agreement occur,  specifically GlaxoSmithKline, LLC submitting an application to use  the license to the FDA, the FDA approving the application, and  issuance of certain patent applications to the Company. The Company  has no further obligations related to these events and therefore  records the amount due into revenue at the time the event occurs.  The Company incurs no additional cost related to these revenues at  the time these events occur.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  On occasion, the Company may enter into a contract that requires  the client to provide an advance payment for specimens that will be  processed at a later date. In these cases, the Company records this  advance as deferred revenue and recognizes the revenue as the  specimens are processed or at the end of the contract period, as  appropriate.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company recorded revenue from pharmaceutical clients for the  three months ended June 30, 2012 and 2013 of $&lt;font style=" FONT-SIZE: 10pt"&gt;1,000,821&lt;/font&gt; and $&lt;font style=" FONT-SIZE: 10pt"&gt;2,207,837&lt;/font&gt;, respectively and for the six  months ended June 30, 2012 and 2013 of $&lt;font style=" FONT-SIZE: 10pt"&gt;2,030,663&lt;/font&gt; and $&lt;font style=" FONT-SIZE: 10pt"&gt;4,649,531&lt;/font&gt;, respectively.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;ResponseDX&lt;/em&gt;&lt;/strong&gt;&lt;sup&gt;&amp;#174;&lt;/sup&gt; &lt;strong&gt;&lt;em&gt;  Revenue&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Revenues that are derived from ResponseDX&lt;sup&gt;&amp;#174;&lt;/sup&gt; testing  services are recognized in accordance with ASC 605, &lt;em&gt;Revenue  Recognition&lt;/em&gt;, which requires that four basic criteria be met  before revenue can be recognized: (1) persuasive evidence that an  arrangement exists; (2) delivery has occurred and title and the  risks and rewards of ownership have been transferred to the client  or services have been rendered; (3) the price is fixed or  determinable; and (4) collectability is reasonably assured. We  record revenues when our tests have confirmed results which is  evidence that the services have been performed.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Revenues are recorded on an accrual basis as the contractual  obligations are completed and as a set of assays is processed  through our laboratory under a specified contractual  protocol.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0in; FONT: 10pt Times New Roman, Times, Serif"&gt;  ResponseDX&lt;sup&gt;&amp;#174;&lt;/sup&gt; Private Payor and Medicare revenues are  recorded at established billing rates less an estimated billing  adjustment, based on reporting models utilizing historical cash  collection percentages and updated for current effective  reimbursement factors. The Company&amp;#8217;s Medicare provider number  allows it to invoice and collect from Medicare. The Company&amp;#8217;s  invoicing to Medicare is primarily based on amounts allowed by  Medicare for the service provided as defined by Common Procedural  Terminology (&amp;#8220;CPT&amp;#8221;).&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The following details ResponseDX&lt;sup&gt;&amp;#174;&lt;/sup&gt; revenue for the  periods indicated:&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="23%" colspan="5"&gt;  &lt;div&gt;Three Months&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="23%" colspan="5"&gt;  &lt;div&gt;Six Months&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="23%" colspan="5"&gt;  &lt;div&gt;Ended June 30,&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="23%" colspan="5"&gt;  &lt;div&gt;Ended June 30,&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="23%" colspan="5"&gt;  &lt;div&gt;(Unaudited)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="23%" colspan="5"&gt;  &lt;div&gt;(Unaudited)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Net Medicare revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,306,989&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,078,473&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,767,307&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,422,688&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Net Private Payor revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,526,684&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,027,604&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,012,327&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,865,886&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Other&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;512&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,353&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Net ResponseDX&amp;#174; revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,834,185&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,106,077&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,785,987&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,288,574&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;u style="TEXT-INDENT: 0.25in; MARGIN: 0in"&gt;&lt;font size="2"&gt;Cost-Containment  Measures&lt;/font&gt;&lt;/u&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Both government and private pay sources have instituted  cost-containment measures designed to limit payments made to  providers of health care services, which include diagnostic test  providers such as the Company, and there can be no assurance that  future measures designed to limit payments made to providers will  not adversely affect the Company.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;u&gt;Regulatory Matters&lt;/u&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  A portion of the Company&amp;#8217;s revenues are derived from Medicare  reimbursement. Laws and regulations governing Medicare programs are  complex and subject to change and to interpretation, and the  Company may be adversely affected by future changes in the  applicable laws and regulations and governmental investigations,  lawsuits or private actions which include mandatory damages, fines,  penalties, criminal charges, loss or suspension of licenses and/or  suspension or exclusion from Medicare and certain other  governmental programs. The Company believes that it is in  compliance with all applicable laws and regulations and is not  aware of any pending or threatened investigations involving  allegations of potential wrongdoing.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Medicare reimbursement rates are subject to regulatory changes and  government funding restrictions. In January 2013, the initial 2013  annual Medicare fee schedule update was announced which included  proposed changes to Medicare reimbursement rates that significantly  reduced the reimbursement rates for certain of the testing services  we provide. The Company is participating with other impacted  organizations to provide guidance to the local Medicare  Administrative Contractor (&amp;#8220;MAC&amp;#8221;) that may result in  adjustments to the proposed reimbursement rates to better reflect  the value of the services being performed. As a result of this  guidance, the local MAC updated certain pricing on or about April  3, 2013 which reflected an increase in many of the tests originally  priced in January 2013. It is uncertain if continued guidance  provided to Medicare and the local MAC by impacted organizations  will result in additional fee increases during 2013. If, however,  the current level of reduction in reimbursement rates is adopted as  is, it may have a material adverse effect on the Company's  operations.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  As a result of these Current Procedural Terminology  (&amp;#8220;CPT&amp;#8221;) code changes and Medicare price changes, we  have experienced a departure from our normal reimbursement patterns  with Medicare and other payors. Specifically, we have experienced  delays in certain reimbursements for services and an increase in  initial denials of claims for certain services provided.  Accordingly, we revaluated the assumptions employed in our model  for estimating revenue to be recognized for  ResponseDX&lt;sup&gt;&amp;#174;&lt;/sup&gt; testing. We view the code and price  changes described above as affecting only the assumptions we used  in pricing our services. The nature of the testing we provide, the  evidence we gather to establish the creditworthiness of our payors  and the delivery method of our services have not changed from prior  periods, and there are no indicators that these assumptions require  change.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We performed an analysis that considered our historical patterns of  revenue by payor in conjunction with the fluctuations we  experienced in the three and six months ended June 30, 2013 to  arrive at the revenue recorded for the quarter. We believe that the  changes in CPT codes and pricing that are causing confusion and  erratic payment experience in the payor community will take some  time to resolve. The time needed for resolution will depend upon  the local MAC releasing additional pricing changes and potentially,  revisions to previously revised prices, and upon the private payor  community adopting the new CPT codes and some level of revised  pricing. Accordingly, our revenue recognition estimates could be  materially affected in future periods as pricing and payments  patterns change and develop, and we may be materially affected by  future or retroactive price changes.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  On July 8, 2013, the Centers for Medicare and Medicaid Services  (&amp;#8220;CMS&amp;#8221;) released a new proposed rulemaking entitled  &amp;#8220;Medicare Program; Revisions to Payment Policies under the  Physician Fee Schedule, Clinical Laboratory Fee Schedule &amp;amp;  Other Revisions to Part B for CY 2014&amp;#8221;. This proposed rule  contains a number of provisions that may adversely impact the level  of reimbursement for a variety of tests for which the Company  receives reimbursement from the Medicare program beginning in 2014.  Among other things, CMS has proposed examining approximately 1,200  laboratory tests that appear on the Clinical Lab Fee Schedule  (CLFS) over a period of five years to determine whether advances in  technology may have reduced the cost of providing such tests and  whether or not the level of reimbursement should be revised. The  Company is currently performing molecular testing which is  reimbursed using CPT codes that fall on the CLFS. CMS has also  proposed changing the methodology used to determine reimbursement  rates for the technical component of certain tests reimbursed off  of the Physician Fee Schedule (PFS). Among other provisions, CMS  has proposed limiting the Relative Value Units (RVUs) ascribed to  the Practice Expense component of their reimbursement formula for  tests performed in &amp;#8220;Non-Facilities&amp;#8221; (which would  include most clinical laboratories like the &lt;font style="BACKGROUND-COLOR: transparent"&gt;Company&amp;#8217;s) to the RVUs that  have been ascribed for the same procedures under the Hospital  Outpatient Prospective Payment System, or the Ambulatory Payment  Classification (APC) system which are used to reimburse  &amp;#8220;Facilities&amp;#8221; (such as hospitals and ambulatory surgery  centers). The Company currently performs FISH testing, which may be  impacted by this PFS rule change if it is enacted. CMS has not yet  proposed any specific rates for CY 2014 and the Company is  examining the potential impact that this type of rule change may  have on its operations. The final CLFS and PFS for CY 2014 are not  expected to be issued until November 2013, and it is likely we will  not know the rates for 2014 until that time. Although we are unable  to quantify the impacts of the proposed rules at this time, if they  are enacted without any changes, it will likely have a material  adverse impact on the Company.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;font style="BACKGROUND-COLOR: transparent"&gt;&lt;/font&gt;&amp;#160;     &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Cost of Revenue&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Cost of revenue represents the cost of materials, direct labor,  royalties, costs associated with processing tissue specimens  including pathological review, staining, microdissection, paraffin  extraction, reverse transcription polymerase chain reaction,  fluorescence in situ hybridization (&amp;#8220;FISH&amp;#8221;), quality  control analyses, license fees and delivery charges necessary to  render an individualized test result. Costs associated with  performing tests are recorded as the tests are processed.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;License Fees&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company licenses technology for the extraction of RNA and DNA  from FFPE tumor specimens from the University of Southern  California (&amp;#8220;USC&amp;#8221;) in exchange for royalty fees on  revenue generated by use of the technology. These royalties are  calculated as a fixed percentage of revenue that we generate from  use of the technology licensed from USC. Total license fees  expensed in cost of revenue under the license agreement with USC  were $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;75,938&lt;/font&gt;&lt;/font&gt; and $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;86,908&lt;/font&gt;&lt;/font&gt;  for the three months ended June 30, 2012 and 2013, respectively,  and were $&lt;font style=" FONT-SIZE: 10pt"&gt;132,440&lt;/font&gt; and $&lt;font  style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;191,014&lt;/font&gt;&lt;/font&gt; for the six months ended  June 30, 2012 and 2013, respectively. We also maintain a  non-exclusive license to use Roche Molecular Systems, Inc.&amp;#8217;s  (&amp;#8220;Roche&amp;#8221;) PCR, homogenous PCR, and reverse  transcription PCR processes. We pay Roche a fixed percentage  royalty fee for revenue that we generate through use of this  technology. Royalties expensed in cost of revenue under the Roche  agreement totaled $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;80,418&lt;/font&gt;&lt;/font&gt; and $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;84,362&lt;/font&gt;&lt;/font&gt;  for the three months ended June 30, 2012 and 2013, respectively,  and totaled $&lt;font style=" FONT-SIZE: 10pt"&gt;143,887&lt;/font&gt; and  $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;174,507&lt;/font&gt;&lt;/font&gt; for the six months ended  June 30, 2012 and 2013, respectively.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  We are subject to potentially significant variations in royalties  recorded in any period. While the amount paid is based on a fixed  percentage from revenues of specific tests pursuant to terms set  forth in the agreements with USC and Roche, the amount due is  calculated based on the revenue we recognize using the respective  licensed technology. As discussed above, this revenue can vary from  period to period as it is dependent on the timing of the specimens  submitted by our clients for testing.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: center; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0in; MARGIN: 0in; FONT: 10pt Times New Roman, Times, Serif"   align="left"&gt;&amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&lt;em&gt;&lt;strong&gt;Research and  Development&lt;/strong&gt;&lt;/em&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company expenses costs associated with research and development  activities as incurred. Research and development &lt;font style="BACKGROUND-COLOR: transparent"&gt;(&amp;#8220;R&amp;amp;D&amp;#8221;) costs are  expensed as incurred and classified as research and development  costs. Certain costs such as lab supplies and reagents that cannot  be specifically identified are allocated based on the number of  samples processed in total by the lab and R&amp;amp;D departments in  total. Research and development costs include employee costs  (salaries, payroll taxes, benefits, and travel), equipment  depreciation and warranties and maintenance, laboratory supplies,  primers and probes, reagents, patent costs and occupancy  costs.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Line of Credit&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  On July 14, 2011, the Company entered into a line of credit  agreement with Silicon Valley Bank (the &amp;#8220;Bank&amp;#8221;). The  agreement has been amended most recently on March 7, 2013. The line  of credit is collateralized by the Company&amp;#8217;s pharmaceutical  and Medicare receivables. The amended maximum amount that can be  borrowed from the credit line is $&lt;font style=" FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt;. As of June 30, 2013, the  amount the Company can draw from the loan was equal to the lesser  of (i) the Company&amp;#8217;s calculated borrowing base, which was 80%  of certain of the Company&amp;#8217;s accounts receivable, or (ii) the  amount available under the credit line. Prior to the line of  credit&amp;#8217;s first amendment on December 14, 2011, the Bank  issued letters of credit up to a maximum amount of $&lt;font style=" FONT-SIZE: 10pt"&gt;500,000&lt;/font&gt;. Any issued letters of credit  reduced the amount available to borrow under the line of credit on  a dollar for dollar basis. As of June 30, 2013, the interest fees  associated with this line of credit were set at the prime rate plus  1%. For the three and six months ended June 30, 2013, the rate  being charged to the Company was 5%. As needed from time to time,  the Company may draw on this line of credit for use for general  corporate purposes. As of December 31, 2012 and June 30, 2013, the  Company has drawn $&lt;font style=" FONT-SIZE: 10pt"&gt;1,000,000&lt;/font&gt;  against the line of credit and no letters of credit were  outstanding. The line of credit is subject to various financial  covenants and, as of June 30, 2013, the Company was in compliance  with these covenants. However, prior to the most recent amendment  on March 7, 2013, the Company was not in compliance with certain  covenants. The September 28, 2012 amendment provided forbearance  for the failure to comply with these certain covenants through  November 30, 2012, and modified the covenants to include a  requirement that the Company maintain account balances at the Bank  totaling a minimum of $&lt;font style=" FONT-SIZE: 10pt"&gt;4,000,000&lt;/font&gt; during the covered forbearance  period. The December 6, 2012 amendment to the agreement extended  the forbearance for the failure to comply with these certain  covenants and the requirement for the Company to maintain account  balances at the Bank totaling a minimum of $4,000,000 through  December 31, 2012. In addition, pursuant to the March 7, 2013  amendment, the Bank waived the Company's existing breach of  financial covenants under the credit agreement and the parties  restructured the line of credit to provide that, among other  things: (i) the revolving line of credit's maturity date was  extended to March 7, 2015, (ii) the fee for the unused portion of  the revolving line of credit was reduced from 0.375% to 0.250% per  annum of the average unused portion of the revolving line of  credit, (iii) the Company must continue to meet certain reporting  requirements including providing financial statements and a  certificate of compliance with the terms and conditions of the  credit agreement by an authorized officer to the Bank within 45  days of the last day of each calendar quarter, provided that if the  Company has less than $4,000,000 in its account at the Bank at any  time during such calendar quarter, the Company must provide the  financial statements and the certificate of compliance within 30  days of the end of such calendar quarter and providing a monthly  report on revenues realized from private payors, (iv) the financial  covenants were amended and restated to require the Company to  maintain a ratio of quick assets to current liabilities of 1:50 to  1:00 and meet certain specified minimum adjusted earnings before  interest, taxes, depreciation and amortization requirements as  defined in the amendment and measured on a monthly basis and (v)  the Bank is granted certain additional inspection of books, records  and collateral rights.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  As of December 31, 2012, the line of credit under the credit  agreement was classified as a current liability of the Company on  the accompanying balance sheet as the line of credit had a maturity  date less than one year from December 31, 2012. As of June 30,  2013, the maturity date of the line of credit has been extended to  March 7, 2015 and therefore the line of credit is classified as a  non-current liability.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  From time to time, the Company&amp;#8217;s calculated borrowing base  under its Bank line of credit may decrease to a level where the  Company is in an over-advance position in which case the Company  will be required to repay any outstanding amounts greater than the  calculated borrowing base for such covered period back to the Bank  immediately. The Company will be able to draw down on the credit  line again with respect to such paid back amount once the Company  is in compliance with the borrowing base requirement.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Income Taxes&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Deferred tax assets and liabilities are determined based on  differences between the financial reporting and tax basis of assets  and liabilities and are measured using the enacted tax rates and  laws that will be in effect when the differences are expected to  reverse. Valuation allowances are established when necessary to  reduce deferred tax assets to the amount expected to be  realized.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, clarifies the accounting for  uncertainty in income taxes recognized in financial statements and  requires the impact of a tax position to be recognized in the  financial statements if that position is more likely than not of  being sustained by the taxing authority. As of December 31, 2012  and June 30, 2013, the Company does not have a liability for  unrecognized tax benefits. The Company recognizes interest and  penalties associated with tax matters as part of the income tax  provision and includes accrued interest and penalties with the  related tax liability in the balance sheet. For the periods ended  June 30, 2012 and 2013, a nominal amount of interest and penalties  were recorded in the Consolidated Statement of Operations.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Stock-Based Compensation&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Stock-based compensation expense for all stock-based compensation  awards granted is based on the grant-date fair value estimated in  accordance with &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 9pt"&gt;accounting  guidance&lt;/font&gt;. The Company recognizes these compensation costs on  a straight-line basis over the requisite service period of the  award, which is generally the option vesting period. As further  described in Note 7, certain awards granted to Thomas Bologna, the  Company&amp;#8217;s Chairman and Chief Executive Officer, were  recognized based on an accelerated vesting basis triggered by  market conditions rather than a straight-line basis.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company accounts for equity instruments issued to non-employees  at fair value using the Black-Scholes option-pricing model and  recognized pursuant to a performance model.&lt;font size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Management Estimates&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The preparation of financial statements in conformity with U.S.  GAAP requires management to make estimates and assumptions that  affect the reported amounts of assets and liabilities and  disclosure of contingent assets and liabilities at the date of the  financial statements and the reported amounts of revenues and  expenses during the reporting period. Significant estimates in  these consolidated financial statements have been made for revenue,  allowances for doubtful accounts, impairment of long-lived assets,  depreciation of property and equipment and stock-based  compensation. Actual results could differ materially from those  estimates.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Long-lived Assets&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Long-lived assets are reviewed for impairment whenever events or  changes in circumstances indicate that the carrying amount of an  asset may not be recoverable. The Company evaluates potential  impairment by comparing the carrying amount of the asset with the  estimated undiscounted future cash flows associated with the use of  the asset and its eventual disposition. Should the review indicate  that the assets cost is not recoverable, the carrying value of the  asset would be reduced to its fair value, which is measured by  future discounted cash flows. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 9pt"&gt;No  impairment charges were recorded during the three and six months  ended June 30, 2012 and 2013.&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Foreign Currency Translation&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The financial position and results of operations of the  Company&amp;#8217;s foreign subsidiary are determined using local  currency as the functional currency. Assets and liabilities of  these operations are translated at the exchange rate in effect at  each period-end.&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 9pt"&gt;Revenues  and expenses&lt;/font&gt; are translated at the average rate of exchange  prevailing during the period. Translation adjustments arising from  the use of differing exchange rates from period to period are  included in accumulated other comprehensive loss in  stockholders&amp;#8217; equity (deficit).&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Comprehensive Loss&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The components of comprehensive loss are accumulated net loss and  foreign currency translation adjustments for the three and six  months ended June 30, 2012 and 2013.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Fair Value of Financial Instruments&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Cash and cash equivalents are stated at cost, which approximates  fair market value. Cash equivalents consist of money market  accounts, with fair values estimated based on quoted market prices.  Debt balances are stated at historical amounts less principal  payments, which approximate fair market value. The Company believes  interest rates in its debt agreements are commensurate with lender  risk profiles for similar companies. For additional information see  Note 12.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Advertising Costs&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  The Company markets its services through its advertising activities  in trade publications and on the internet. Advertising costs are  included in selling and marketing expenses on the statements of  operations and are expensed as incurred. Advertising costs for the  three months ended June 30, 2012 and 2013 were $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;4,090&lt;/font&gt;&lt;/font&gt;  and $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;3,324&lt;/font&gt;&lt;/font&gt;, respectively, and for the  six months ended June 30, 2012 and 2013 were $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;12,971&lt;/font&gt;&lt;/font&gt;  and $&lt;font style="COLOR: black"&gt;&lt;font style=" FONT-SIZE: 10pt"&gt;3,324&lt;/font&gt;&lt;/font&gt;, respectively.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  &lt;strong&gt;&lt;em&gt;Concentration of Credit Risk and Clients and Limited  Suppliers&lt;/em&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Cash and cash equivalents are maintained at financial institutions  and, at times, balances may exceed federally insured limits. The  Company has never experienced any losses related to these balances.  All of the Company&amp;#8217;s non-interest bearing cash balances were  fully insured at December 31, 2012 due to a temporary federal  program in effect from December 31, 2011 through December 31, 2012.  Under this temporary&amp;#160;program, there was no limit to the amount  of insurance for eligible accounts. Beginning on January 1, 2013,  federal insurance coverage reverted to $250,000 per depositor at  each financial institution, and the Company&amp;#8217;s non-interest  bearing cash balances again exceeded federally insured limits.  There were no funds in interest-bearing accounts that exceeded the  federally insured limits as of June 30, 2013. At June 30, 2013,  $&lt;font style=" FONT-SIZE: 10pt"&gt;6,972&lt;/font&gt; of cash was held  outside of the United States.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;font  size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Revenue sources that account for greater than 10 percent of total  revenue are provided below.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="32%" colspan="12"&gt;  &lt;div&gt;Three&amp;#160;Months&amp;#160;&lt;br/&gt;   Ended&amp;#160;June&amp;#160;30,&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="32%" colspan="12"&gt;  &lt;div&gt;Six&amp;#160;Months&amp;#160;&lt;br/&gt;   Ended&amp;#160;June&amp;#160;30,&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="5"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="5"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="5"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="5"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%" colspan="12"&gt;  &lt;div&gt;(Unaudited)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%" colspan="12"&gt;  &lt;div&gt;(Unaudited)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Percent&lt;br/&gt;   of&amp;#160;Total&lt;br/&gt;   Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Percent&lt;br/&gt;   of&amp;#160;Total&lt;br/&gt;   Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Percent&lt;br/&gt;   of&amp;#160;Total&lt;br/&gt;   Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="7%" colspan="2"&gt;  &lt;div&gt;Percent&lt;br/&gt;   of&amp;#160;Total&lt;br/&gt;   Revenue&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="32%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%"&gt;  &lt;div&gt;GlaxoSmithKline, LLC and GlaxoSmithKline Biologicals  S.A.&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;235,917&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;6&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;1,679,175&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;32&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;955,004&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;12&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;3,035,559&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;28&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="32%"&gt;  &lt;div&gt;Medicare, net of contractual allowances&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;1,306,989&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;34&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;1,078,473&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;20&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;2,767,307&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;35&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;2,422,688&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="6%"&gt;  &lt;div&gt;22&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 8pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;  Customers that account for greater than 10 percent of gross  accounts receivable are provided below.&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="clear:both;BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="54%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="21%" colspan="5"&gt;  &lt;div&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="21%" colspan="5"&gt;  &lt;div&gt;As&amp;#160;of&amp;#160;June&amp;#160;30,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="54%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="21%" colspan="5"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="21%" colspan="5"&gt;  &lt;div&gt;(Unaudited)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="54%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%" colspan="2"&gt;  &lt;div&gt;Receivable&lt;br/&gt;   Balance&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%" colspan="2"&gt;  &lt;div&gt;Percent&amp;#160;of&lt;br/&gt;   Total&lt;br/&gt;   Receivables&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%" colspan="2"&gt;  &lt;div&gt;Receivable&lt;br/&gt;   Balance&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%" colspan="2"&gt;  &lt;div&gt;Percent&amp;#160;of&lt;br/&gt;   Total&lt;br/&gt;   Receivables&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="54%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 26px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="54%"&gt;  &lt;div&gt;GlaxoSmithKline, LLC and GlaxoSmithKline&lt;br/&gt;   Biologicals S.A.&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;1,691,144&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;27&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;1,721,048&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;23&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="54%"&gt;  &lt;div&gt;Medicare, net of contractual allowances&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;890,936&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;14&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;1,930,801&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="9%"&gt;  &lt;div&gt;26&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;%&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; BACKGROUND-COLOR: transparent; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"   title="Excluded"&gt;Many of the supplies and reagents used in the  Company&amp;#8217;s testing process are procured from a limited number  of suppliers. Any supply interruption or an increase in demand  beyond the suppliers&amp;#8217; capabilities could have an adverse  impact on the Company&amp;#8217;s business. Management believes it can  identify alternative sources, if necessary, but it is possible such  sources may not be identified in sufficient time to avoid an  adverse impact on its business. Refer also to Note 6 for further  discussion regarding these supply agreements.&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 9pt" title="Excluded"&gt;  The Company made approximately &lt;font style=" FONT-SIZE: 10pt"&gt;  69&lt;/font&gt;% of its reagent purchases from two suppliers during the  three months ended June 30, 2012 and made approximately &lt;font  style=" FONT-SIZE: 10pt"&gt;93&lt;/font&gt;% of its reagent purchases from  four suppliers during the three months ended June 30,  2013.&amp;#160;&lt;/font&gt; The Company made approximately &lt;font style=" FONT-SIZE: 10pt"&gt;69&lt;/font&gt;% of its reagent purchases from two  suppliers during the six months ended June 30, 2012 and made  approximately &lt;font style=" FONT-SIZE: 10pt"&gt;92&lt;/font&gt;% of its  reagent purchases from four suppliers during the six months ended  June 30, 2013.&lt;/div&gt;  &lt;/div&gt;        </NonNumbericText><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>nonnum:textBlockItemType</ElementDataType><SimpleDataType>na</SimpleDataType><ElementDefenition>The entire disclosure for all significant accounting policies of the reporting entity.</ElementDefenition><ElementReferences>Reference 1: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 3

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790



Reference 2: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 1

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790



Reference 3: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 6

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790



Reference 4: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 2

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790



Reference 5: http://www.xbrl.org/2003/role/presentationRef

 -Publisher FASB

 -Name Accounting Standards Codification

 -Topic 235

 -SubTopic 10

 -Section 50

 -Paragraph 5

 -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790



</ElementReferences><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Summary of Significant Accounting Policies</Label></Row></Rows><Footnotes /><IsEquityReport>false</IsEquityReport><ReportName>Summary of Significant Accounting Policies</ReportName><MonetaryRoundingLevel>UnKnown</MonetaryRoundingLevel><SharesRoundingLevel>UnKnown</SharesRoundingLevel><PerShareRoundingLevel>UnKnown</PerShareRoundingLevel><ExchangeRateRoundingLevel>UnKnown</ExchangeRateRoundingLevel><HasCustomUnits>true</HasCustomUnits><IsEmbedReport>false</IsEmbedReport><IsMultiCurrency>false</IsMultiCurrency><ReportType>Sheet</ReportType><RoleURI>http://www.responsegenetics.com/role/SummaryOfSignificantAccountingPolicies</RoleURI><NumberOfCols>1</NumberOfCols><NumberOfRows>2</NumberOfRows></InstanceReport>
